MedImmune, AstraZeneca’s biologic research and development arm, announced that it is expanding its collaboration with the University of California, San Francisco (UCSF), to focus on basic research and translational sciences into diseases involving the Respiratory, Inflammation and Autoimmunity (RIA) fields. The partnership continues joint work begun in 2014, and the two will initiate about a half-dozen research projects…
1. Genentech’s PF Drug Esbriet Shown To Lower Mortality Rates in New Study Read the article here: https://bit.ly/1URSd1G 2. Esbriet’s Promise and Potential as a PF Therapy Read the article here: https://bit.ly/1kub6MJ 3. Phase III Trials…
A retrospective study analyzing data on insurance claims from patients with idiopathic pulmonary fibrosis (IPF) revealed that the disease is associated with a significant economic and healthcare burden. The study, titled “Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study,” was published in the…
A new study from the Children’s Hospital of Chongqing Medical University, China, reports that the drug fasudil helps to prevent lung fibrosis development in newborn rats exposed to prolonged oxygen treatment by blocking the Rho/ROCK signaling pathway. While high levels of oxygen given to at-risk newborn infants is a life-saving procedure, researchers and clinicians know that prolonged exposure…
The Pulmonary Fibrosis Foundation (PFF) Care Center Network recently announced the addition of UT Medicine San Antonio to its group of medical centers specialized in the treatment of pulmonary fibrosis (PF). The designation acknowledges UT Medicine’s comprehensive, multidisciplinary approach to providing top-quality care to PF patients and their families. The PFF…
In a new study, researchers applied a novel anti-scarring paste to animal models with radiation-induced fibrosis and observed a healing and preventive effect. Such results indicate a promising therapeutic effect of A2A receptor blocker-derived drugs, such as this paste, for conditions like scleroderma and interstitial pulmonary fibrosis. The research paper,…
Reata Pharmaceuticals recently announced the recruitment of the first patient with pulmonary hypertension associated with interstitial lung disease (PH-ILD) in their Phase 2 LARIAT clinical trial evaluating the efficacy, safety, and tolerability of experimental therapy bardoxolone methyl in the treatment of patients with pulmonary hypertension (PH). The recent enrollment is part of…
A new study reported that patients with newly diagnosed idiopathic pulmonary fibrosis (IPF) often experience lung function decline, which furthers disease progression. The study, titled “Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis,” was published in the journal…
In a new study entitled “The matrix protein Fibulin-5 lies at the interface of tissue stiffness and inflammation in fibrosis,” an international team of scientists discovered a new protein – Fibulin-5 – involved in skin fibrosis, and with potential therapeutic implications in fibrosis in other organs, including…
Spherix Global Insights, GmbH, a business intelligence and market research company based on Switzerland, recently reported a study revealing that idiopathic pulmonary fibrosis (IPF) remains a challenge in terms of treatment, especially since the majority of patients are diagnosed at already advanced disease stages. The Spherix study is entitled “…
Get regular updates to your inbox.
